多药耐药基因蛋白P-gp和ABCG2在喉癌等头颈肿瘤中的作用及相关信号通路  

Roles of multidrug resistance proteins P-gp and ABCG2 in laryngocatcinoma and their related signal pathways

作　　者：苏甜甜[1] 张佳[1] 孙臻峰[1] 

机构地区：[1]上海交通大学附属上海市第一人民医院耳鼻咽喉头颈外科,上海200080

出　　处：《山东大学耳鼻喉眼学报》2016年第3期103-106,共4页Journal of Otolaryngology and Ophthalmology of Shandong University

摘　　要：喉癌作为恶性实体肿瘤,化学药物疗法在其综合治疗中扮演着日益重要的角色,但多药耐药(MDR)的产生成为导致化疗失败的主要原因。研究表明,多药耐药基因蛋白P-gp和ABCG2在喉癌的MDR中起着重要作用,P-gp和ABCG2之间或正或负呈相关性,其相关信号通路(M APK)与P-gp和ABCG2在肿瘤中的表达也有一定的相关性,但其调控因素及如何由此提高化疗效果有待进一步研究。Laryngocatcinoma is a type of malignant solid tumor,and chemotherapy plays an increasingly important role in its treatment,but multidrug resistance（ MDR） has become the leading cause of chemotherapy failure. Researches have showed that P-gp and ABCG2 proteins are important in the MDR of laryngocatcinoma,P-gp may be positively or negatively correlated with ABCG2,and their related signal pathways（ MAPK） are related to their expressions in tumors. However,howP-gp and ABCG2 are controlled and howto improve the effect of chemotherapy remain to be further investigated.

关 键 词：喉肿瘤 多药耐药 P-GP ABCG2 

分 类 号：R739.65[医药卫生—肿瘤]